Patent Grant
10426958
Described herein are devices and methods for increasing ocular mucin and other tear protein release using intranasally delivered electrical stimulation. The devices may deliver electrical stimulation to the nasal mucosa to trigger degranulation of conjunctival goblet cells, which in turn releases secretory mucins into the tear fluid. The intranasal stimulation may also trigger release of lysozyme, lactoferrin, and other tear proteins into the aqueous layer of the tear film. The methods may further comprise obtaining feedback relating to the efficacy of the delivered electrical stimulation by measuring impedance or an electromyogram (EMG) signal.
Dry eye is thought to stem from abnormalities of the tear film on the surface of the eye. The tear film includes three layers, an inner mucus layer, an outer lipid layer, and an aqueous layer between them. The mucus layer, which is primarily composed of mucins, is the thinnest layer and functions to adhere the tear film to the eye.
Mucins are high molecular weight glycoproteins that have various functions. Some mucins are secreted into the mucous layer while others form the glycocalyx (transmembrane mucins), which is the specific structure that adheres the tear film to the eye. The glycocalyx is partially embedded in the lipid bilayer of corneal and conjunctival epithelial cells and forms a hydrophilic network that binds secreted mucins in the mucus layer to these cells. Additionally, the mucins in the mucus layer and glycocalyx are believed to attract water, thereby decreasing the surface tension of the tear film and facilitating the even spread of the aqueous layer on the eye, which in turn may protect the eye from pathogens and make the ocular surface less susceptible to damage. Mucins that have been detected in the tear film include MUC1, MUC2, MUC4, MUC5AC, MUC7, MUC13, MUC15, MUC16, and MUC 17. Transmembrane mucins include MUC1, MUC4, MUC13, MUC15, MUC16, and MUC17. Secreted mucins include MUC2, MUC5AC, and MUC7, which can be further classified as gel-forming or soluble. MUC5AC has been identified as a secreted, gel-forming mucin. Mucins found on the ocular surface are primarily produced by goblet cells (e.g., secreted mucin MUC5AC), apical cells of the conjunctiva and cornea (e.g., transmembrane mucins MUC1, MUC2 and MUC4), and the lacrimal gland (e.g., secreted mucin MUC7). In addition to mucins, the lacrimal gland secretes proteins into the aqueous layer that promote spreading of the tear film and that help maintain a healthy environment on the ocular surface. Exemplary proteins include lysozyme, lactoferrin, tear specific prealbumin, caeruloplasmin, lacitin, lipophilin, and immunoglobulins A, D, G, and E.
Decreased mucin and tear protein levels have been associated with dry eye. Common treatment approaches are typically palliative in nature, attempting to supplement the patient's natural tears or improve the residence time of the limited tear volume already present on the ocular surface (Dry Eye Workshop 2007. The Epidemiology of Dry Eye Disease. Ocul. Sur. 2007; 5(2): 93-107). These treatment approaches have had limited success. It would therefore be desirable to have an improved treatment that increases mucin and other tear protein levels in the tear film.
Described herein are devices and methods for increasing mucin release on the ocular surface of a subject. The devices may be stimulator devices configured to contact the nasal mucosa and intranasally deliver an electrical stimulus. In some instances, the stimulator devices are configured as handheld stimulators. The electrical stimulus is capable of increasing the mucin concentration in the tear film by, e.g., triggering degranulation of goblet cells in the conjunctiva of the eye.
The methods for increasing mucin on an ocular surface of a subject generally comprise intranasally delivering an electrical stimulation to the subject, and stimulating release of an ocular mucin, where the released ocular mucin improves a condition of the eye. The intranasally delivered electrical stimulation may be delivered for at least 10 seconds, and in some instances, for at least three minutes, and may be repeated as desired. The electrical stimulation is generally intranasally delivered to the nasal mucosa. Additionally or alternatively, the intranasal delivery of electrical stimulation may include delivering an electrical stimulus comprising a waveform having on and off periods.
Electrical stimulation may be intranasally delivered using a stimulator, where the stimulator comprises a stimulator body and a stimulator probe, and further where the stimulator probe comprises at least one nasal insertion prong. A portion of the nasal insertion prong may be placed in contact with the nasal mucosa as part of the stimulation delivery process. The nasal insertion prong may include various types of electrodes, however, it may be useful for the electrode to comprise a hydrogel. The stimulator body may be sized for holding in one hand. Some variations of the stimulator probe may include two nasal insertion prongs. In these variations, the two nasal insertion prongs may be biased toward each other, and the bias used to promote stimulation of the septum of the nasal cavity and/or to hold the stimulator in the nose during intranasal delivery of the electrical stimulation.
The intranasally delivered electrical stimulation may stimulate release of an ocular mucin. Exemplary ocular mucins include without limitation, MUC1, MUC2, MUC4, MUC5AC, MUC7, MUC13, MUC15, MUC16, and MUC 17. Some of these mucins, e.g., MUC5AC, may be released by stimulating degranulation of goblet cells. Various parameters of the electrical stimulation waveforms may be tailored to achieve goblet cell degranulation or release of a particular type of ocular mucin from other cells, e.g., apical cells or acinar cells. In some instances, intranasal stimulation may decrease the concentration of certain inflammatory mediators in the tear film.
The intranasally delivered electrical stimulation may also be used in methods that increase the release of tear proteins in the aqueous layer of the tear film or the concentration of tear proteins in the aqueous layer of the tear film. These tear proteins include without limitation, lysozyme, lactoferrin, tear specific prealbumin, caeruloplasmin, lacitin, lipophilin, and immunoglobulins A, D, G, and E.
The methods for increasing mucin and other tear proteins on the ocular surface may further include identifying an optimal stimulation location for intranasally delivering the electrical stimulation. The optimal stimulation location may be identified via impedance monitoring. Additionally or alternatively, the optimal stimulation location may be identified by obtaining feedback from an electromyogram (EMG) signal from a facial muscle near the nose, cheeks, or around the eyes. The impedance and EMG signals may be measured intranasally using the same device that delivers the electrical stimulation. In other instances, the impedance and EMG signals are measured by an extranasal device. One or more parameters of the electrical stimulation waveforms may be tailored or optimized to achieve release of the tear proteins from secretory vesicles of the lacrimal gland.
Methods for treating dry eye are also described herein. The methods generally include intranasally delivering electrical stimulation to a subject afflicted with dry eye; obtaining feedback relating to the efficacy of the delivered electrical stimulation by measuring impedance or an electromyogram (EMG) signal from a facial muscle near the nose, cheeks, or around the eyes of the subject; formulating a treatment plan based on the feedback; and continuing intranasal delivery of the electrical stimulation according to the treatment plan, where the delivered electrical stimulation increases the release of a tear protein to treat the dry eye of the subject. The tear protein can be mucin, lysozyme, lactoferrin, tear specific prealbumin, caeruloplasmin, lacitin, lipophilin, and immunoglobulins A, D, G, and E, or a combination thereof.
Additionally or alternatively, the methods for treating dry eye may include determining whether a subject afflicted with dry eye is deficient in a tear protein on an ocular surface, and based on the tear protein found to be deficient, intranasally delivering an electrical stimulation to the subject, where one or more parameters of the intranasally delivered electrical stimulation is selected based upon the deficient tear protein, and where the intranasally delivered electrical stimulation is effective to increase the release or the concentration of the deficient tear protein on the ocular surface. The tear protein can be mucin, lysozyme, lactoferrin, tear specific prealbumin, caeruloplasmin, lacitin, lipophilin, and immunoglobulins A, D, G, and E, or a combination thereof. In some instances, the methods may include determining a type of dry eye in a subject and intranasally delivering to the subject an electrical stimulation according to a treatment plan based on the determined type of dry eye, e.g., mild dry eye, moderate dry eye, or severe dry eye.
Intranasally delivered electrical stimulation and release of ocular mucins and other tear proteins may improve dry eye and ocular inflammation, as well as other ocular conditions. The methods described herein may further be combined with additional treatments, such as the application of artificial tears to the ocular surface, use of one or more punctum plugs, and/or the application of an active agent to the ocular surface. Here, for example, the active agent may comprise one more antibacterial agents, one or more anti-inflammatory agents, one or more antihistamines, one or more steroids, or combinations thereof.
Described here are devices and methods for increasing tear protein release using intranasal stimulation. Tear proteins include mucins, which are secreted into the mucin layer of the tear film, and proteins secreted by the lacrimal gland into the aqueous layer of the tear film. In some variations, the devices and methods are configured to deliver an electrical stimulus to the nasal mucosa to cause mucin release, e.g., by stimulating degranulation of goblet cells. Increased mucin production may be useful in 1) adhering the tear film to the ocular surface; 2) enhancing lubrication of the ocular surface; 3) preventing break-up of the tear film; 4) capturing dust, allergens, and bacteria, which in turn may reduce the sensory input that drives the inflammatory/histamine response in the eye; and 5) preventing desiccation of corneal and/or conjunctival epithelial cells. In other variations, the devices and methods are configured to deliver an electrical stimulus to the nasal mucosa to cause secretion of other tear proteins from the lacrimal gland into the aqueous layer of the tear film, e.g., lysozyme, lactoferrin, tear specific prealbumin, caeruloplasmin, lacitin, lipophilin, and immunoglobulins A, D, G, and E. Increased tear protein secretion may be useful in promoting spreading of the tear film and controlling infectious agents on the ocular surface, as well as and regulating the osmotic balance of the ocular surface.
The tear film maintains the transparency and health of the cornea, and is generally comprised of three layers, including an outer lipid layer 100, a middle aqueous layer 102, and an inner mucus layer 104, as shown in
The inner mucus layer is primary comprised of mucins. Goblet cells, which are modified simple columnar epithelial cells found in the conjunctiva of the eye (e.g., bulbar conjunctiva 200 shown in
In patients with dye eye, the proper amount of mucins in the tear film may be lacking. The abnormal mucin production may be due to systemic diseases (e.g., Sjögren's syndrome), medications, or other causes. In some variations, the methods described herein may use application of intranasal stimulation to increase mucin release into the tear film. Additionally or alternatively, the methods described herein may use intranasal stimulation to increase mucin release by triggering goblet cell degranulation (i.e., release of mucin-containing vesicles/granules).
Intranasal stimulation may in part increase mucin secretion through modulating parasympathetic innervation of goblet cells in the conjunctiva. More particularly, afferent parasympathetic stimulation with particular waveforms (described in detail elsewhere herein) may increase the secretory drive of goblet cells. In some variations, intranasal stimulation may increase mucin release by stimulating the pterygopalatine ganglion (PPG) via the greater petrosal nerve. In other variations, repeated and/or sustained intranasal stimulation over a period of time may improve release of mucin from goblet cells (goblet cell degranulation) and/or increase the number/density of goblet cells in the conjunctiva.
Devices and Systems
Generally, the devices and methods described herein may comprise a stimulator configured to deliver an electrical stimulus to the inner cavity of the nose. The instrument consists of four distinct parts: 1) A reusable base unit, which produces the electrical stimulation waveform, 2) A disposable tip assembly that inserts into the nasal cavity and stimulates the target intranasal tissue, 3) A reusable cover to protect the tip assembly, 4) A charger, which recharges the battery inside the base unit. Some variations of the stimulation systems described here may comprise a handheld stimulator.
The stimulator body 402 may comprise a user interface 530 comprising one or more operating mechanisms to adjust one or more parameters of the stimulus. The operating mechanisms may provide information to the control subsystem 436, which may comprise a processor 532, memory 534, and/or stimulation subsystem 536. In some variations, the operating mechanisms may comprise first and second buttons 414 and 416. In some variations, pressing the first button 414 may turn on the stimulator and/or change one or more parameters of the stimulus (e.g., increase the intensity of the stimulus, change the stimulation pattern, or the like), while pressing the second button 416 may turn off the stimulator and/or change one or more parameters of the stimulus (e.g., decrease the intensity of the stimulus, change the stimulation pattern, or the like). Additionally or alternatively, the user interface may comprise one or more feedback elements (e.g., based on light, sound, vibration, or the like). As shown, the user feedback elements may comprise light-based indicators 418, which may provide information to the user, as described in more detail below.
In the variation shown in
The stimulus may be delivered to a subject via the stimulator probe 404. In some variations the stimulator body 402 and stimulator probe 404 may be reversibly attachable. Some or all of the stimulator 400 may be disposable. For example, in some variations the stimulator body may be permanently attached to the stimulator probe, and the entire stimulator may be disposable. In other variations, one or more portions of the stimulator 400 may be reusable. For example, in variations where the stimulator probe 404 is releasably connected to the stimulator body 402, the stimulator body 402 may be reusable, and the stimulator probe 404 may be disposable and periodically replaced.
The stimulator probe 404 may comprise at least one nasal insertion prong, which may be configured to be at least partially inserted into the nasal cavity of a subject. In the handheld stimulator variation shown in
In some variations, the nasal insertion prongs may be parallel when not inserted into the nose of a subject, but may have sufficient flexibility to allow the prongs to self-align to the desired stimulation location when inserted into a user's nasal cavities. In other variations of stimulators comprising two nasal insertion prongs, however, the nasal insertion prongs may not be parallel to each other when not inserted into the nose of a subject; that is, the nasal insertion prongs may be positioned at an angle relative to each other. For example,
In some variations in which the stimulator comprises two nasal insertion prongs biased toward each other, the return bias may be sufficient to hold the stimulator in place. In these variations, once positioned in the nasal cavities, the distal ends of the nasal insertion prongs may press against tissue with sufficient force to allow for hands-free use—that is, the user may not need to hold the stimulator in order for the electrodes to remain in apposition with the target tissue. This may improve ease of use. In other variations, the return bias may be sufficient to reduce unintended movement of the nasal insertion prongs while inserted, while still requiring the stimulator to be held.
The devices (and systems) described herein may additionally or alternatively also comprise other features to allow hands-free or reduced-handling use. For example, the system may comprise a strap configured to be placed around a user's head and attached to the stimulator to hold the stimulator in place during stimulation. The strap may be removably attachable to the stimulator, or in other variations may be permanently attached to the stimulator. In some variations of stimulators configured for hands-free use, the stimulators may be configured to be inserted and/or removed by a user. In other variations, the stimulators may be configured to be inserted/removed by a medical professional.
For example,
In some variations, the clip 702 may comprise a u-shaped portion 714 configured to receive and clamp to a portion of the nasal septum 708. This engagement between the clip 702 and the nasal septum 708 may limit advancement of the stimulator 700 into the nose (e.g., to prevent over-insertion of the stimulator 700). The clip 702 may exert sufficient pressure on the septum 708 so as to resist removal of the stimulator 700 from the nose. Accordingly, the clip 702 may allow the stimulator to be positioned in the nose of a subject, and the subject may wear the stimulator without needing to actively hold the stimulator in the nose. The clip 702 may be removed by flexing the clip 702 to disengage it from the septum. As such, the subject may be able to insert and remove the stimulator 700 him- or herself. In some variations, the clip 702 may be at least partially formed from one or more shape memory materials (e.g., a nickel-titanium alloy), such that the clip 702 may be deformed to disengage the clip 702 from the septum 708 and may return to its original shape. In some variations an exterior portion of the clip 702 may be formed from one or more insulating materials, such as described herein (e.g., PTFE, silicone, combinations thereof, or the like), and an interior portion may include an electrically conductive core (e.g., a wire of any suitable metal, such as silver, stainless steel, platinum, alloys thereof, or the like) electrically connecting the first stimulator unit 704 to the second stimulator unit 706. In these variations, the insulating outer portion of the clip 702 may prevent inadvertent electrical stimulation between the clip 702 and the subject.
Generally, each stimulator unit may comprise one or more electrodes 716. In some variations, it may be desirable for the stimulator units to comprise a radially expandable structure that may expand to contact the nasal mucosa when inserted into the nostrils. While shown in
Generally, the first 704 and/or second 706 stimulator units may comprise a housing 720, which may comprise a control subsystem having a processor, a stimulation subsystem, and a memory. In some variations the control subsystem may have a detection subsystem. Additionally or alternatively, the stimulator may comprise a communication subsystem. The stimulator circuitry may be housed in a single housing 720 (e.g., a housing 720 of the first stimulator unit 704 or a housing 720 of the second stimulator unit), or may be divided between multiple housings (e.g., a housing 720 of the first stimulator unit 704 and a housing 720 of the second stimulator unit). In some variations, the stimulator 700 may comprise a power source (e.g., a battery) (not shown). In other variations, the stimulator 700 may be powered wirelessly (e.g., via power received from a coil 718 or other antenna).
In some variations, the stimulators described here may comprise a cap to protect the stimulator probe. For example,
Other variations and features of stimulator systems, devices, and their method of use suitable for employment in the methods described herein are described in U.S. patent application Ser. No. 14/256,915, filed Apr. 18, 2014, and titled “NASAL STIMULATION DEVICES AND METHODS”; in U.S. patent application Ser. No. 14/630,471, filed on Feb. 24, 2015, and titled “POLYMER FORMULATIONS FOR NASOLACRIMAL STIMULATION”; in U.S. patent application Ser. No. 14/920,860, filed Oct. 22, 2015, and titled “STIMULATION DEVICES AND METHODS FOR TREATING DRY EYE”; and in U.S. patent application Ser. No. 14/920,852, filed Oct. 22, 2015, and titled “IMPLANTABLE NASAL STIMULATOR SYSTEMS AND METHODS,” each of which is hereby incorporated by reference in its entirety.
Methods
Described herein are methods for increasing mucin and other tear proteins on an ocular surface of a subject. The methods generally include intranasally delivering an electrical stimulation to the subject, e.g., to the nasal mucosa of the subject. The intranasally delivered electrical stimulation may stimulate release of one or more ocular mucins to thereby improve a condition of the eye. In some instances, the intranasally delivered electrical stimulation stimulates or increases mucin release by stimulating/triggering degranulation of goblet cells in the conjunctiva of the eye. Additionally or alternatively, the intranasally delivered electrical stimulation may help to increase tear volume on the eye, e.g., by increasing the volume of the aqueous layer. Tear meniscus height (TMH) measurements can be used assess tear volume. Additionally or alternatively, the intranasally delivered electrical stimulation may be useful in decreasing the concentration of inflammatory mediators in the tear film, or decreasing a particular type of inflammatory mediator, e.g., MMP-9 or IL-8, in the tear film.
Release of Ocular Mucins
The stimulators and methods described herein may deliver waveforms configured to stimulate release of one more ocular mucins, as further described below. In some variations, the waveforms may be pulse-based. The waveforms may be configured to stimulate tissue on both sides of the nose, or the waveforms may be configured to stimulate tissue on a single side of the nose. In other variations, the waveform may comprise symmetric biphasic pulses. The waveform may be programmed to include any suitable parameters (e.g., frequency, pulse width, amplitude) in order to enhance or trigger mucin release. In addition to the waveforms described herein, exemplary waveforms that may be used for intranasal stimulation are described in U.S. patent application Ser. No. 14/809,109, filed Jul. 24, 2015, and titled “STIMULATION PATTERNS FOR TREATING DRY EYE,” which is hereby incorporated by reference in its entirety.
Electrical stimulation may be intranasally delivered for at least 5 minutes, at least 4 minutes, at least 3 minutes, at least 2 minutes, at least 1 minute, at least 30 seconds, at least 15 seconds, at least 10 seconds, or at least 5 seconds. In one variation, the electrical stimulation may be intranasally delivered for a duration of 3 minutes or at least 3 minutes. In other variations, the electrical stimulation may be intranasally delivered for a duration ranging from 30 seconds to one 1 minute, from 30 seconds to 1.5 minutes (90 seconds), from 30 seconds to 2 minutes (120 seconds), from 30 seconds to 2.5 minutes (150 seconds), or from 30 seconds to 3 minutes (180 seconds). The electrical stimulation may be repeated any number of times using the same waveform or a different waveform.
Generally, the stimulus may comprise a waveform of less than about 200 Hz. In some of these variations, the frequency is preferably between about 10 Hz and about 200 Hz. In some of these variations, the frequency is preferably between about 30 Hz and about 150 Hz. In others of these variations, the frequency is preferably between about 50 Hz and about 80 Hz. In others of these variations, the frequency is preferably between about 30 Hz and about 60 Hz. In some variations, the frequency may be about 1.5 Hz, about 10.25 Hz, about 70 Hz, about 150 Hz, about 25 Hz, about 27.5 Hz, about 30 Hz, about 32.5 Hz, about 35 Hz, about 37.5 Hz, about 40 Hz, about 42.5 Hz, about 45 Hz, about 47.5 Hz, about 50 Hz, about 52.5 Hz, about 55 Hz, about 57.5 Hz, about 60 Hz, about 62.5 Hz, or about 65 Hz.
Generally, when the stimulus comprises a biphasic pulse and the first phase of the biphasic pulse is current-controlled, the first phase may preferably have an amplitude between about 1.0 mA and about 10 mA. Amplitudes within these ranges may be high enough to stimulate targeted tissue, but sufficiently low as to avoid any significant heating of tissue, ablation of tissue, or the like. In some variations the amplitude may be between about 1.0 mA and about 5.0 mA. In other variations, the first phase may have an amplitude of about 0.1 mA, about 0.2 mA, about 0.3 mA, about 0.4 mA, about 0.5 mA, about 0.6 mA, about 0.7 mA, about 0.8 mA, about 0.9 mA, or about 1.0 mA. In some variations, the amplitude may be variable. For example, the amplitude may vary between about 1.3 mA and about 1.5 mA, about 2.2 mA and about 2.5 mA, about 3.2 mA and about 3.7 mA, about 4.3 mA and about 5.0 mA. When the first phase of a biphasic pulse is voltage-controlled, the first phase may preferably have an amplitude between about 10 mV and about 100 V.
When a stimulator is configured to deliver a pulse-based waveform, in some variations, the amplitude of the pulses may be constant over time. In other variations, the amplitude of the pulses may vary over time. This may reduce subject accommodation to the stimulation. In some variations, the amplitude of pulses may increase (linearly, exponentially, etc.) from a minimum value to a maximum value, drop to the minimum value, and repeat as necessary. In some variations, the amplitude of the pulses may vary according to a sinusoidal profile. In another variation, as illustrated in
In some variations in which the amplitude varies over time, the amplitude may vary at a frequency suitable for reducing subject accommodation or increasing subject comfort, such as between about 0.1 Hz and about 5 Hz, between about 1 Hz and about 5 Hz, between about 1 Hz and 2 Hz, between about 2 Hz and 3 Hz, between about 3 Hz and 4 Hz, or about 4 Hz and about 5 Hz. In some variation, the amplitude may vary at a frequency of about 1.0 Hz, about 1.1 Hz, about 1.2 Hz, about 1.3 Hz, about 1.4 Hz, about 1.5 Hz, about 1.6 Hz, about 1.7 Hz, about 1.8 Hz, about 1.9 Hz, about 2.0 Hz, about 2.1 Hz, about 2.2 Hz, about 2.3 Hz, about 2.4 Hz, about 2.5 Hz, about 2.6 Hz, about 2.7 Hz, about 2.8 Hz, about 2.9 Hz, about 3.0 Hz, about 3.1 Hz, about 3.2 Hz, about 3.3 Hz about 3.4 Hz, about 3.5 Hz, about 3.6 Hz, about 3.7 Hz, about 3.8 Hz, about 3.9 Hz, or about 4.0 Hz. In other variations, the stimulation waveform may be a modulated high frequency signal (e.g., sinusoidal), which may be modulated at a beat frequency of the ranges described above. In such variations, the carrier frequency may be between about 100 Hz and about 100 kHz.
When the stimulus comprises a biphasic pulse, the first phase may preferably have a pulse width between about 1 μs and about 10 ms. In some of these variations, the pulse width may be between about 10 μs and about 100 μs. In other variations, the pulse width may be between about 100 μs and about 1 ms. In yet other variations, the pulse width may be between about 0 μs and about 300 μs. In yet other variations, the pulse width may be between about 0 μs and 500 μs.
In some variations, the pulse width may be constant over time. In other variations, the pulse width may vary over time. Pulse width modulation over time may increase the efficacy and/or comfort of the stimulation. In some variations, the pulse width may increase (linearly, exponentially, etc.) from a minimum value to a maximum value, drop to the minimum value, and repeat as necessary. In some variations, the pulse width may vary according to a sinusoidal profile. In another variation, as illustrated in
In some variations, the increase and decrease of pulse width may be defined by a function implemented by the stimulator. For example, the pulse width may be defined by a function such that the pulse width varies exponentially. In one variation, the function defining pulse width may comprise two phases—a first phase during which the pulse width of the leading pulse increases over time, and a second phase during which the pulse width of the leading pulse decreases over time. During the first phase, the pulse width of the leading pulse approaches the maximum pulse width according to an exponential function, where at time t, PW{t} is defined by the equation
where PWmax is the maximum allowed pulse width, PWmin is the minimum allowed pulse width, and τ is a time constant.
Once a predetermined amount of time has elapsed (a multiple of time constant τ), the pulse width modulation may enter the second phase. During the second phase, the pulse width of the leading pulse exponentially decays from its maximum value to a minimum value following the exponential equation
After a predetermined amount of time has elapsed (a multiple of time constant τ), the pulse width modulation may re-enter the first phase, and the cycle may repeat. The pulse width of the secondary (charge balancing) pulse is increased and decreased accordingly to retain charge full balancing. PWmax, PWmin, and τ may have any suitable values to achieve the pulse widths described herein, but in one example the waveform may have a PWmax of 300 μs, PWmin of 0 μs, and τ of ⅕ μs. In other variations, for example, PWmax, may be about 100 μs, about 200 μs, about 300 μs, about 400 μs, or about 500 μs; PWmin may be about 0 μs, about 10 μs, about 50 μs, or about 100 μs; and τ may be about ⅓ μs, about ¼ μs, about ⅕ μs, or about ⅙ μs. An exemplary function defining exponentially increasing and decaying pulse widths is shown in
In some instances, the waveforms may be delivered in a continuous fashion, while in other instances, the waveforms may be delivered in a non-continuous fashion having on periods and off periods. Exemplary on/off durations include without limitation, 1 second on/1 second off, 1 second on/2 seconds off, 2 seconds on/1 seconds off, 5 seconds on/5 seconds off, 0.2 seconds on/0.8 seconds off, less than 1 second on/less than 10 seconds off. Non-continuous delivery with on and off periods may help to reduce subject accommodation and/or may be more effective than continuous delivery in causing mucin release.
Some variations of the methods described herein may comprise adjusting the waveform parameters based on feedback. In some variations the feedback may help to adjust the stimulus to be maximally effective in causing mucin release. Additionally or alternatively, the feedback may help to adjust the stimulus to prevent accommodation while limiting unpleasant sensations, such as a feeling of needing to sneeze.
The stimulators described herein may be used to intranasally deliver an electrical stimulation to increase release of one or more ocular mucins in the tear film, as previously stated. The methods may comprise intranasally delivering the stimulation to trigger goblet cell degranulation, mucin secretion from corneal, conjunctival, and/or apical cells into the tear film and/or glycocalyx. The intranasally delivered stimulation may also be used to promote sustained increases in mucin content of tears.
Ocular mucins include without limitation, MUC1, MUC2, MUC4, MUC5AC, MUC7, MUC13, MUC15, MUC16, and MUC 17. These ocular mucins may further be characterized as secreted mucins and transmembrane mucins. Exemplary secreted mucins are MUC2, MUC5AC, and MUC7. Exemplary transmembrane mucins include MUC1, MUC4, MUC13, MUC15, MUC16, and MUC17. In some variations, the intranasally delivered electrical stimulation may be used to increase release of secreted mucin MUC5AC. Referring to the Examples, the study described in Example 1 demonstrated that intranasally delivered electrical stimulation increases the release of MUC5AC by stimulating degranulation of conjunctival goblet cells. Differences between healthy (control) subjects and those with dry eye were noted by histology (not shown) from conjunctival samples obtained by impression cytology and then stained for MUC5AC and by Periodic acid-Schiff (PAS), and by a comparison of ratios of degranulated to non-degranulated cells in the samples obtained before and after sham (extranasal) stimulation and intranasal stimulation. Upon staining, non-degranulated goblet cells were typically defined by their uniform size, intact cell borders, and intracellularly packaged mucins, while degranulated goblet cells were characterized by disrupted cell borders and scattered mucin granules. In some instances, PAS and MUC5AC stained specimens revealed clusters of degranulated goblet cells after intranasal stimulation. These clusters were not observed in cytology specimens taken at baseline and after extranasal stimulation. The stimulator used for such stimulation was similar to the device described in
Specifically, the results obtained from MUC5AC staining indicated that the ratio of degranulated to non-degranulated goblet cell densities from subjects with dry eye was significantly higher after intranasal stimulation (4.71±4.48) compared to those taken at baseline (0.74±0.62, p<0.001) and after sham stimulation (0.57±0.54, p<0.001). See Table 1 in Example 1 for a complete listing of results after stimulation. PAS staining also demonstrated a significant increase in the ratio of degranulated to non-degranulated goblet cell densities after the delivery of intranasal stimulation in dry eye subjects (2.02±1.41) compared to those taken at baseline (0.73±0.36, p=0.001) and after sham stimulation (0.69±0.39, p=0.001). See Table 4 in Example 1 for a complete listing of results after stimulation.
Additional results obtained from inferior bulbar (IB) conjunctiva and temporal bulbar (TB) conjunctiva cytology specimens taken from all study participants and stained for MUC5AC revealed a significantly higher ratio of degranulated to non-degranulated goblet cells after intranasal stimulation (IB: 2.28±1.27 and TB: 1.81±1.01) compared to baseline (IB: 0.56±0.55, p=0.015) (TB: 0.56±0.32, p=0.003) and extranasal sham application (IB: 0.37±0.29, p=0.001) (TB: 0.39±0.33, p=0.001). When the same analysis was repeated in the dry eye or control groups, the ratio was significantly higher after intranasal stimulation than the baseline ratio and ratio after extranasal application in both groups (p<0.05). Moreover, while control subjects had a higher ratio of degranulated to non-degranulated goblet cells at baseline (0.75±0.52) compared to the dry eye group (0.41±0.27), the ratio became slightly higher in dry eye (2.04±1.12 vs. 1.99±1.21 in control) after intranasal stimulation application. A significant increase in the mean degranulated goblet cell density was also observed after intranasal stimulation. There was no significant difference between the IB or TB conjunctiva locations in terms of the effectiveness of the intranasal stimulation application on conjunctival goblet cell secretory response.
Data obtained from a single center, single-arm, study that included 15 dry eye subjects (22 eyes) specifically relating to morphological goblet cell changes before and after three minutes of intranasal stimulation showed a significant reduction in goblet cell area and perimeter. These results are provided in Example 4. Other image data that was obtained (not shown) before and after stimulation demonstrated that ocular goblet cells are smaller post nasal stimulation, indicating that ocular mucins are being released from the conjunctiva right on the eye and not just the conjunctiva of the eye lid.
In some variations, the intranasally delivered electrical stimulation may be used to increase release of a transmembrane mucin. For example, the intranasally delivered electrical stimulation may be used to increase release of MUC1, MUC4, MUC13, MUC15, MUC16, MUC17, or combinations thereof. Referring to
In general, the ocular glycocalyx in combination with other mucins provides a covering over the ocular surface, and helps to shield the ocular surface from bacteria, dust, and allergens, as previously stated. Given that intranasal stimulation may stimulate release of mucin from goblet cells, and may stimulate release of proteins in the lacrimal tears, a complete glycocalyx may be formed that may be beneficial to the healing process of corneal/conjunctival tissue. With a complete glycocalyx, symptoms due to allergy and/or eye dryness may be reduced. Mucin further functions as lubricant and/or cushion between the ocular surface and the eye lids that helps protect against scratching of the ocular surface. Accordingly, in some variations, increasing mucin release via intranasal stimulation may be performed as desired to help extend the comfortable wear time for contact lenses.
The stimulation may be delivered to the nasal mucosa. In some instances, the targeted area may comprise tissue innervated by the anterior ethmoidal branch of the nasociliary nerve. In some instances, the targeted area may comprise tissue innervated by the nasopalatine nerve. In some instances, the targeted area of the nasal mucosa may be superior to the columella. It may in some instances be near the inferior end of the nasal bone (i.e., near the interface between the nasal bone and the upper lateral cartilage). As such, the stimulus may be delivered between about 20 mm and about 35 mm into the nasal cavity of the patient, in some cases via an electrode between about 25 mm and about 35 mm into the nasal cavity of the patient. In other instances, the targeted area may be the columella. It may be desirable that the stimulus be delivered in the anterior portion of the nasal cavity, within the nostrils and anterior to the turbinates, and in some instances, at a location anterior to the middle turbinate, or at a location anterior to the inferior turbinate. The stimulus may be delivered at least partially through tissue of or near the septum, and it may in some instances be desirable to direct the stimulus such that a portion is directed toward the front of the nose. This may allow for selective activation of nerves in the front of the septum (e.g., the ophthalmic branch of the trigeminal nerve) while minimizing activation of nerves toward the rear of the nasal septum, which may reduce negative side effects that may occur from stimulation of nerves that innervate the teeth, and which may reduce rhinorrhea. It may also in some instances be desirable to direct the stimulus so as to reduce negative side effects that may occur from stimulation of the olfactory area.
The methods described herein may comprise intranasally delivering stimulation according to one or more treatment regimens. For example, to increase mucin release, stimulation may be delivered to a subject as needed and/or according to a predetermined plan. In some variations, it may be desirable that each round of stimulation is long enough to result in acute mucin secretion. Intranasal stimulation may be employed for about 30 seconds to about 1 minute to achieve mucin release. At 30 seconds of stimulation, some mucin release may be obtained while at 1 minute, the release of mucin may be more robust due to, e.g., the longer stimulation triggering a larger number of goblet cells to degranulate or the longer stimulation allowing more mucin to be released from goblet cells. It may in some instances take several or more minutes of intranasal stimulation to achieve mucin release. For example, in a patient with severe dry eye, it may take about 5 to 10 minutes to achieve mucin release, while in a patient with moderate dry eye, it may take about 3 to 5 minutes to achieve mucin release, while in a patient without dry eye, it may take only about 1 minute to achieve mucin release with particular stimulus parameters. In some variations, the methods described herein may comprise an initial round of stimulation that is longer than subsequent rounds of stimulation. The initial round of stimulation may in some variations be of a length sufficient to achieve mucin release in a patient with dry eye who has not previously been treated with electrical intranasal stimulation.
The initial round of stimulation may in some methods be performed under the supervision of a medical professional, while subsequent rounds of stimulation may be performed without supervision of a medical professional (e.g., at home). In some variations, the initial and subsequent rounds of stimulation may be delivered using different stimulators. These stimulators may be configured with different waveforms, and/or may have different physical configurations. For example, the initial round of stimulation may be delivered using a stimulator configured for hands-free use (e.g., may comprise nasal insertion prongs biased toward each other and/or a strap to hold the nasal insertion prongs in a subject's nose), while subsequent rounds of stimulation may be delivered using a stimulator not configured for hands-free use (e.g., a stimulator not comprising a strap and having parallel nasal insertion prongs). As another example, a stimulator used under supervision of a medical professional (e.g., for the initial round of stimulation) may be fully disposable, while a stimulator used without such supervision (e.g., for subsequent stimulation rounds) may be at least partially reusable.
In some variations, the intranasally delivered electrical stimulation may help to increase tear volume on the eye, e.g., by increasing the volume of the aqueous layer. Tear meniscus height (TMH) measurements can be used assess tear volume. For example, and as provided in Example 2 and
Additionally or alternatively, the intranasally delivered electrical stimulation may be useful in decreasing the concentration of inflammatory mediators in the tear film, or decreasing a particular type of inflammatory mediator, e.g., MMP-9 or IL-8, in the tear film. For example, as provided in Example 3 and
The intranasally delivered electrical stimulation may be used to improve or treat various ocular surface diseases or various conditions of the eye. For example, the intranasal stimulation may be used to improve dry eye or ocular inflammation. In one variation, the intranasal stimulation may be used to improve dry eye or ocular inflammation associated with Sjögren's syndrome. In other variations, the condition of the eye is an unstable tear film or an unstable glycocalyx. Intranasal stimulation to increase mucin release for these conditions may optionally be used in conjunction with other therapies. In some variations, the intranasally delivered electrical stimulation is used in conjunction with one or more punctum plugs. In other variations, the intranasal stimulation may be administered in conjunction with application of one or more active agents, e.g., cyclosporine or lifitegrast, to the ocular surface. The one or more active agents may comprise one or more antibacterial agents, one or more anti-inflammatory agents, one or more antihistamines, one or more immunomodulators, one or more immunohistomodulators, or combinations thereof. Patients receiving intranasal stimulation may also be treated with topical treatments (e.g., artificial lubricants (e.g., lipid-based artificial tears), topical steroids, topical cyclosporine, topical lifitegrast, topical azithromycin, topical antibiotics (e.g., bacitracin)), topical antihistamines, oral antihistamines, oral antibiotics (e.g., oral tetracycline, oral doxycycline), nutritional supplements (e.g., fish oil, gamma-linolenic acid), and combinations thereof. In some variations, the intranasally delivered electrical stimulation is delivered in response to symptomatic need. In other variations, the intranasally delivered electrical stimulation is delivered to avoid a symptomatic need.
Studies conducted by the inventors thus far have captured the release of MUC5AC as the predominant mucin in the eye. However, there are other ocular mucins, as noted herein, and these mucins have different functions. Some function more as glue to keep the tears up longer (increasing tear film stability and tear film breakup time), while others encapsulate dust, allergens, bacteria etc. By encapsulating these “intruders,” mucins function together with the “glycocalyx” (
Release of Other Tear Proteins
In patients with dye eye, the proper amount of tear proteins in the aqueous layer of the tear film may be lacking, in addition to, or alternatively to, mucin. The abnormal tear protein production may be due to systemic diseases (e.g., Sjögren's syndrome), medications, or other causes. In some variations, the methods described herein may use the application of intranasal stimulation, in the same manner as described for mucin, to increase other tear protein release into the tear film, e.g., the aqueous layer of the tear film.
Accordingly, methods for increasing secretion of tear proteins other than mucin on the ocular surface by intranasally delivering electrical stimulation to a subject are also described herein. For example, secretion of tear proteins such as lysozyme, lactoferrin, tear specific prealbumin, caeruloplasmin, lacitin, lipophilin, immunoglobulins such as IgA, IgD, IgE, and IgG, or combinations thereof, can be triggered by intranasally delivering electrical stimulation. The intranasal stimulation may be delivered for at least 5 minutes, at least 4 minutes, at least 3 minutes, at least 2 minutes, at least 1 minute, at least 30 seconds, at least 15 seconds, at least 10 seconds, or at least 5 seconds. In some instances, the electrical stimulation may be intranasally delivered for a duration of 3 minutes or at least 3 minutes. In other instances, the electrical stimulation may be intranasally delivered for a duration ranging from 30 seconds to one 1 minute, from 30 seconds to 1.5 minutes (90 seconds), from 30 seconds to 2 minutes (120 seconds), from 30 seconds to 2.5 minutes (150 seconds), or from 30 seconds to 3 minutes (180 seconds). Some variations of the method may include delivering intranasal stimulation to a subject for about 3 minutes to increase lysozyme and/or lactoferrin secretion into the tear fluid and onto the ocular surface. Referring to Example 5, data illustrating the increase in lysozyme and lactoferrin concentrations as compared to controls after intranasal stimulation application is provided. The electrical stimulation may be repeated any number of times using the same waveform or a different waveform.
Optimizing Intranasal Delivery of Electrical Stimulation
In general, aqueous tear production is readily sensed by a subject. However, the subject may not be able to identify when tear components such as mucin or other tear proteins are released. Accordingly, in addition to the intranasal delivery of electrical stimulation, the methods may comprise obtaining feedback relating to the efficacy of the delivered electrical stimulation by measuring impedance or an electromyogram (EMG) signal. Impedance may reflect the efficacy of the delivered electrical stimulation by indicating that sufficient current is able to flow from the stimulator into tissue. An EMG signal may reflect the efficacy of the delivered electrical stimulation because in some instances, neural stimulation of the anterior ethmoidal nerve may trigger muscle contractions of the orbicularis oculi and muscles on the cheek and of the nose as the patient controls an urge to sneeze. As such, EMG signals measured from facial muscles of the nose, cheeks and around the eyes (e.g., the orbicularis oculi) may provide feedback relating to the efficacy with respect to mucin and/or other tear protein secretion.
These forms of feedback, such as impedance or an EMG signal may be used, for example, to confirm that a stimulus is being effectively delivered for the intended stimulation duration. For example, this feedback may be used to confirm that the stimulus is being effectively delivered at the beginning of a round of stimulation and/or at one or more time points during the round of stimulation. When a round of stimulation has a particular length (e.g., at least about 30 seconds of stimulation), these forms of feedback may be used to confirm that the full duration of effective stimulation is delivered. As described herein, intranasal stimulation may be employed for about 30 seconds to about 1 minute to achieve mucin release. At 30 seconds of stimulation, some mucin release may be obtained while at 1 minute, the release of mucin may be more robust due to, e.g., the longer stimulation triggering a larger number of goblet cells to degranulate or the longer stimulation allowing more mucin to be released from goblet cells. As such, it may be desirable to confirm that stimulation is effectively delivered for the full desired duration.
The impedance and/or EMG signal may be measured using the same device that delivers the electrical stimulation. For example, the stimulators described herein may be configured to measure impedance and/or an EMG at or near the stimulus delivery electrodes. In other instances, the impedance and/or EMG signal may be measured using a separate device (i.e., not the same device as the device that delivers the electrical stimulation). For example, the impedance and/or EMG signal may be measured by a separate intranasal or extranasal device. In some variations, the extranasal device may comprise a nose strip comprising detection electrodes placed on the outside of the nose.
The methods for increasing mucin and other tear proteins on the ocular surface may further include identifying an optimal stimulation location for intranasally delivering the electrical stimulation. Finding the optimal stimulation location can be accomplished by guidance or training by the physician, as further described below. Techniques for identifying the optimal stimulation location can include impedance monitoring. Additionally or alternatively, the optimal stimulation location can be identified by obtaining feedback from an electromyogram (EMG) signal from a facial muscle near the nose, cheeks, or around the eyes (e.g., the orbicularis oculi). The impedance and EMG signals can be measured intranasally using the same device that delivers the electrical stimulation. In other instances, the impedance and EMG signals can be measured by an extranasal device. In some variations, the extranasal device comprises a nose strip.
The delivery of intranasal stimulation can also be accomplished via a treatment plan that optimizes one or more stimulation parameters, e.g., duration of stimulation, frequency of the stimulation waveform, and amplitude of the stimulation waveform, and/or finds the optimal location to stimulate in order to effect the desired response. As further described herein, the treatment plan may be formulated under guidance or training by a physician. One or more parameters of the electrical stimulation waveforms may be tailored or optimized to achieve release of mucin and other tear proteins from secretory vesicles of the lacrimal gland. The one or more optimized parameters can be selected from the group consisting of duration of stimulation, type of stimulation waveform, frequency of the stimulation waveform, amplitude of the stimulation waveform, pulse width of the stimulation waveform, and combinations thereof. In some variations, the one or more optimized parameters is duration of stimulation. It may be useful for the duration of stimulation to range from about 30 seconds to about 3 minutes, or from about 30 seconds to about 1 minute. Additionally or alternatively, the one or more optimized parameters is amplitude of the stimulation waveform.
Methods for treating dry eye are also described herein. The methods generally include intranasally delivering electrical stimulation to a subject afflicted with dry eye; obtaining feedback relating to the efficacy of the delivered electrical stimulation by measuring impedance or an electromyogram (EMG) signal from a facial muscle near the nose, cheeks, or around the eyes of the subject; formulating a treatment plan based on the feedback; and continuing intranasal delivery of the electrical stimulation according to the treatment plan, where the delivered electrical stimulation increases the release of a tear protein to treat the dry eye of the subject. Exemplary tear proteins include without limitation, mucin, lysozyme, lactoferrin, tear specific prealbumin, caeruloplasmin, lacitin, lipophilin, and immunoglobulins A, D, G, and E, and combinations thereof. The methods for treating dry eye can further include identifying an optimal stimulation location for intranasally delivering the electrical stimulation. Finding the optimal stimulation location can be accomplished by guidance or training by the physician, as further described below. Techniques for identifying the optimal stimulation location can include impedance monitoring. Additionally or alternatively, the optimal stimulation location can be identified by obtaining feedback from an electromyogram (EMG) signal from a facial muscle near the nose, cheeks, or around the eyes (e.g., the orbicularis oculi). The impedance and EMG signals can be measured intranasally using the same device that delivers the electrical stimulation. In other instances, the impedance and EMG signals can be measured by an extranasal device. In some variations, the extranasal device comprises a nose strip.
The delivery of intranasal stimulation can also be accomplished via a treatment plan that optimizes one or more stimulation parameters, e.g., duration of stimulation, frequency of the stimulation waveform, and amplitude of the stimulation waveform, and/or finds the optimal location to stimulate in order to effect the desired response. As further described herein, the treatment plan may be formulated under guidance or training by a physician. One or more parameters of the electrical stimulation waveforms may be tailored or optimized to achieve release of mucin and other tear proteins from secretory vesicles of the lacrimal gland. The one or more optimized parameters can be selected from the group consisting of duration of stimulation, type of stimulation waveform, frequency of the stimulation waveform, amplitude of the stimulation waveform, pulse width of the stimulation waveform, and combinations thereof. In some variations, the one or more optimized parameters is duration of stimulation. It may be useful for the duration of stimulation to range from about 30 seconds to about 3 minutes, or from about 30 seconds to about 1 minute. Additionally or alternatively, the one or more optimized parameters is amplitude of the stimulation waveform.
Other methods for treating dry eye may include determining whether a subject afflicted with dry eye is deficient in a tear protein on an ocular surface, and based on the tear protein found to be deficient, intranasally delivering an electrical stimulation to the subject, where one or more parameters of the intranasally delivered electrical stimulation is selected based upon the deficient tear protein, and where the intranasally delivered electrical stimulation is effective to increase release or the concentration of the deficient tear protein on the ocular surface. Exemplary tear proteins include without limitation, mucin, lysozyme, lactoferrin, tear specific prealbumin, caeruloplasmin, lacitin, lipophilin, and immunoglobulins A, D, G, and E, and combinations thereof.
In some instances, the methods may include determining a type of dry eye in a subject and intranasally delivering to the subject an electrical stimulation according to a treatment plan based on the determined type of dry eye, e.g., mild dry eye, moderate dry eye, or severe dry eye. Guidance and training may be offered by the physician so that the subject learns how to properly use the stimulator device according to their treatment plan.
Examples 1-3 below relate to a three-visit study consisting of one screening opthalmological examination and two separate treatment visits for a total of 15 participants (10 with dry eye, and 5 normal). In one treatment visit, the participants were subjected to extranasal (sham) stimulation, and in the other visit, to intranasal stimulation. The types of stimulation were performed in randomized order.
Stimulation was performed for three minutes using a handheld stimulation device as described in
Results from the IC relating to the degranulation of goblet cells are described in Example 1. Furthermore, tear meniscus height measurements and tear fluid samples were collected before and after each stimulation, as described in Examples 2 and 3.
After staining, five images from each membrane were captured at ×20 magnification with a fluorescence microscope. In these images, the ratio of degranulated to non-degranulated GC densities (GCDs) was measured as a marker of mucin release/secretion. While non-degranulated GCs were typically well defined by their uniform size, intact cell borders, and intracellularly packaged mucins, degranulated GCs were characterized by disrupted cell borders and scattered mucin granules.
The goblet cell density data was analyzed using SPSS 20.0 for Mac (SPSS Inc., Chicago, Ill., USA). Prior to statistical analysis, data distribution was checked for normality. Because of the sample size, non-parametric tests were preferred in the analysis. The Mann-Whitney U test was used to compare differences between two independent groups. The Wilcoxon signed-rank test was used when comparing repeated measurements. A p-value of less than 0.05 was considered as statistically significant.
The results obtained from MUC5AC staining indicated that intranasal stimulation significantly increased the degranulated to non-degranulated goblet cell density ratio in the conjunctiva of subjects with dry eye as compared to normal/healthy subjects. The degranulated to non-degranulated goblet cell density ratio data is provided below in Table 1, and graphically represented in
Data obtained from the MUC5AC staining also demonstrated that goblet cell degranulation occurred in various areas of the conjunctiva on the eye (bulbar conjunctiva). IC samples taken from the inferior bulbar conjunctiva (IB) and temporal bulbar conjunctiva (TB) of subjects with dry eye and normal/healthy subjects showed an increase in degranulated goblet cell densities, as provided below in Table 2, and graphically represented in
Additionally, among dry eye participants, data obtained from the MUC5AC staining of IB and TB revealed a significantly higher ratio of degranulated to non-degranulated GCDs after intranasal stimulation compared to baseline and extranasal (sham) stimulation application (Table 3 and
Results obtained from the PAS staining were also statistically significant. As provided in Table 4 and
Data obtained from PAS staining also demonstrated that goblet cell degranulation occurred in various areas of the conjunctiva on the eye (bulbar conjunctiva). IC samples taken from the inferior bulbar conjunctiva (IB) and temporal bulbar conjunctiva (TB) of subjects with dry eye and normal/healthy subjects showed an increase in degranulated goblet cell densities, as provided below in Table 5, and graphically represented in
During the treatment visits outlined above, tear meniscus height was measured by AS-OCT (Anterior Optical Coherence Tomography) (RTVue; Optovue INC., Fremont, Calif.) before and after stimulation applications. The study eye was the eye with the lowest tear meniscus height prior to the first stimulation application, or, if both eyes were equal, the right eye was considered the study eye.
As shown by the data in Table 6, which is graphically represented in
During the treatment visits outlined above, tear fluid was collected before and after each intranasal and extranasal stimulation. Tear samples were collected using a microcapillary tube from the tear lake near the temporal canthus without touching the globe. Tear collection continued until a maximum of 5 μL was collected from each eye, or until 5 minutes had elapsed.
The tear samples were analyzed for a variety of factors and inflammatory mediators. Although not statistically significant, there was a decrease in MMP-9 and IL-8 concentrations in the tear samples after the intranasal application of stimulation, which appeared to more be prominent in the dry eye group. MMP-9 concentration data from subjects who revealed a decrease compared to controls after intranasal stimulation application are provided in Table 7 and in
Data relating to morphological goblet cell (GC) changes before and after intranasal stimulation was obtained from a single center, single-arm, study that included 15 dry eye subjects (22 eyes). Intranasal stimulation was delivered using a handheld stimulation device as described in
Laser in vivo corneal confocal microscopy (laser IVCM) images were taken before and after approximately three minutes of intranasal stimulation application at the inferonasal area of the bulbar conjunctiva. GCs were analyzed and measured by ImageJ™ software. Three images from each subject were selected according to their quality and accuracy to be further analyzed by two masked observers. GCs were selected according to the following criteria: 50<area<150 μm2, round or oval shaped, highlighted from the background, and well defined borders. All data are shown as mean±SD. Mean data were compared using a paired t-test. P values <0.05 were considered statistically significant.
Morphological analysis was performed for a total of 755 GCs pre- and 712 GCs post-application of the intranasal stimulation. Mean pre- and post-GC areas were 67.52±40.03 μm2 and 58.72±31.16 μm2, respectively. The mean change in area, 8.8±8.8 μm, representing a 13.03% reduction following use of the stimulation device, was statistically significant (p<0.001). Mean pre- and post-stimulation GC perimeters were 48.78±21.84 μm and 42.79±19.25 μm, respectively. The mean change in perimeter, 5.99±2.59 μm, representing a 12.27% reduction following use of the intranasal stimulator, was statistically significant (p<0.001).
Overall, a comparison of the laser IVCM images showed a significant reduction in GC area and perimeter within three minutes of stimulation, demonstrating a direct effect on GCs.
Increased aqueous tear production after intranasal stimulation was demonstrated in Example 2. In this Example, intranasal stimulation was also shown to promote release of other proteins from secretory granules in the lacrimal gland.
Fifty-five (55) dry eye subjects were enrolled in a single-arm study. Intranasal stimulation was delivered to the subjects using a handheld stimulation device as described in
Data from the single-arm study is provided below as mean±SD (standard deviation). Mean differences in concentration (post-stimulation minus pre-stimulation) were evaluated by determining an equivalence margin and comparing the 95% confidence interval (CI) of the mean difference to the margin.
Mean pre-stimulation and post-stimulation total protein concentrations were 12.6±5.0 μg/μl and 11.9±4.0 μg/μl, respectively. An equivalence margin of ±2.52 μg/μl (20% of the pre-stimulation mean) was used to evaluate the equivalence of pre-stimulation and post-stimulation total protein concentration. The 95% CI [−2.11, 0.58], of the mean difference in total protein concentration (−0.76±4.85 μg/μl), fell within the equivalence margin. An equivalence margins of 0.20 μg/μl (20% of the pre-stimulation relative means) was used to evaluate the equivalence of the relative amounts of pre-stimulation and post-stimulation lysozyme and lactoferrin concentration. The 95% CI [−0.02, 0.09], of the mean difference in relative lysozyme concentration (−0.04±0.19), and the 95% CI [0.005, 0.22], of the mean difference in relative lactoferrin concentration (0.11±0.37), both fell within the equivalence margins.
This application claims priority to U.S. Provisional Application No. 62/263,498 filed on Dec. 4, 2015; U.S. Provisional Application No. 62/321,170 filed on Apr. 11, 2016; U.S. Provisional Application No. 62/330,744 filed on May 2, 2016; and U.S. Provisional Application No. 62/376,834 filed on Aug. 18, 2016. Each of the foregoing disclosures is hereby incorporated by reference in its entirety.
| Number | Name | Date | Kind |
|---|---|---|---|
| 2512882 | Truesdale | Jun 1950 | A |
| 2525381 | Tower | Oct 1950 | A |
| 3620219 | Barker | Nov 1971 | A |
| 3709228 | Barker et al. | Jan 1973 | A |
| 3885550 | MacLeod | May 1975 | A |
| D257495 | Bros et al. | Nov 1980 | S |
| 4495676 | Hartmetz | Jan 1985 | A |
| 4520825 | Thompson et al. | Jun 1985 | A |
| 4539988 | Shirley et al. | Sep 1985 | A |
| 4590942 | Brenman et al. | May 1986 | A |
| 4628933 | Michelson | Dec 1986 | A |
| 4681121 | Kobal | Jul 1987 | A |
| 4684362 | Holt | Aug 1987 | A |
| 4706680 | Keusch et al. | Nov 1987 | A |
| 4735207 | Nambu et al. | Apr 1988 | A |
| 4777954 | Keusch et al. | Oct 1988 | A |
| 4780932 | Bowman et al. | Nov 1988 | A |
| 4868154 | Gilbard et al. | Sep 1989 | A |
| 4926880 | Claude et al. | May 1990 | A |
| 4957480 | Morenings | Sep 1990 | A |
| 4988358 | Eppley et al. | Jan 1991 | A |
| 5025807 | Zabara | Jun 1991 | A |
| 5072724 | Marcus | Dec 1991 | A |
| 5078733 | Eveleigh et al. | Jan 1992 | A |
| 5090422 | Dahl et al. | Feb 1992 | A |
| 5099829 | Wu | Mar 1992 | A |
| 5147284 | Fedorov et al. | Sep 1992 | A |
| 5324316 | Schulman et al. | Jun 1994 | A |
| 5342410 | Braverman | Aug 1994 | A |
| 5345948 | O'Donnell, Jr. | Sep 1994 | A |
| 5360438 | Fisher | Nov 1994 | A |
| 5498681 | Askari et al. | Mar 1996 | A |
| 5514131 | Edwards et al. | May 1996 | A |
| 5533470 | Rose | Jul 1996 | A |
| 5545617 | Dartt et al. | Aug 1996 | A |
| 5571101 | Ellman et al. | Nov 1996 | A |
| 5607461 | Lathrop | Mar 1997 | A |
| 5611970 | Apollonio et al. | Mar 1997 | A |
| 5640978 | Wong | Jun 1997 | A |
| 5683436 | Mendes et al. | Nov 1997 | A |
| 5697957 | Noren et al. | Dec 1997 | A |
| 5707400 | Terry et al. | Jan 1998 | A |
| 5713833 | Milligan | Feb 1998 | A |
| 5720773 | Lopez-Claros | Feb 1998 | A |
| 5733282 | Ellman et al. | Mar 1998 | A |
| 5735817 | Shantha | Apr 1998 | A |
| 5792100 | Shantha | Aug 1998 | A |
| 5794614 | Gruenke et al. | Aug 1998 | A |
| 5800685 | Perrault | Sep 1998 | A |
| 5843140 | Strojnik | Dec 1998 | A |
| 5900407 | Yerxa et al. | May 1999 | A |
| 5904658 | Niederauer et al. | May 1999 | A |
| 5935155 | Humayun et al. | Aug 1999 | A |
| 5948006 | Mann | Sep 1999 | A |
| 6001088 | Roberts et al. | Dec 1999 | A |
| 6020445 | Vanderlaan et al. | Feb 2000 | A |
| 6035236 | Jarding et al. | Mar 2000 | A |
| 6050999 | Paraschac et al. | Apr 2000 | A |
| 6051017 | Loeb et al. | Apr 2000 | A |
| 6083251 | Shindo | Jul 2000 | A |
| 6102847 | Stielau | Aug 2000 | A |
| 6152916 | Bige | Nov 2000 | A |
| 6205359 | Boveja | Mar 2001 | B1 |
| 6208902 | Boveja | Mar 2001 | B1 |
| 6240316 | Richmond et al. | May 2001 | B1 |
| 6246911 | Seligman | Jun 2001 | B1 |
| 6270796 | Weinstein | Aug 2001 | B1 |
| 6272382 | Faltys et al. | Aug 2001 | B1 |
| 6275737 | Mann | Aug 2001 | B1 |
| 6277855 | Yerxa | Aug 2001 | B1 |
| 6284765 | Caffrey | Sep 2001 | B1 |
| 6324429 | Shire et al. | Nov 2001 | B1 |
| 6327504 | Dolgin et al. | Dec 2001 | B1 |
| 6366814 | Boveja et al. | Apr 2002 | B1 |
| 6405079 | Ansarinia et al. | Jun 2002 | B1 |
| 6438398 | Pflugfelder et al. | Aug 2002 | B1 |
| 6458157 | Suaning | Oct 2002 | B1 |
| 6505077 | Kast et al. | Jan 2003 | B1 |
| 6526318 | Ansarinia et al. | Feb 2003 | B1 |
| 6535766 | Thompson et al. | Mar 2003 | B1 |
| 6537265 | Thanavala et al. | Mar 2003 | B2 |
| 6539253 | Thompson et al. | Mar 2003 | B2 |
| 6562036 | Ellman et al. | May 2003 | B1 |
| 6564102 | Boveja | May 2003 | B1 |
| 6578579 | Burnside et al. | Jun 2003 | B2 |
| 6604528 | Duncan | Aug 2003 | B1 |
| 6641799 | Goldberg | Nov 2003 | B2 |
| 6658301 | Loeb et al. | Dec 2003 | B2 |
| 6662052 | Sarwal et al. | Dec 2003 | B1 |
| 6684879 | Coffee et al. | Feb 2004 | B1 |
| 6701189 | Fang et al. | Mar 2004 | B2 |
| 6748951 | Schmidt | Jun 2004 | B1 |
| 6792314 | Byers et al. | Sep 2004 | B2 |
| 6829508 | Schulman et al. | Dec 2004 | B2 |
| 6853858 | Shalev | Feb 2005 | B2 |
| 6871099 | Whitehurst et al. | Mar 2005 | B1 |
| 6879859 | Boveja | Apr 2005 | B1 |
| 6885888 | Rezai | Apr 2005 | B2 |
| 6895279 | Loeb et al. | May 2005 | B2 |
| 7024241 | Bornzin et al. | Apr 2006 | B1 |
| 7054692 | Whitehurst et al. | May 2006 | B1 |
| 7067307 | Hochleitner et al. | Jun 2006 | B2 |
| 7069084 | Yee | Jun 2006 | B2 |
| 7117033 | Shalev et al. | Oct 2006 | B2 |
| 7142909 | Greenberg et al. | Nov 2006 | B2 |
| 7146209 | Gross et al. | Dec 2006 | B2 |
| 7169163 | Becker | Jan 2007 | B2 |
| 7190998 | Shalev et al. | Mar 2007 | B2 |
| 7225032 | Schmeling et al. | May 2007 | B2 |
| 7228184 | Heath | Jun 2007 | B2 |
| 7247692 | Laredo | Jul 2007 | B2 |
| 7317947 | Wahlstrand et al. | Jan 2008 | B2 |
| 7330762 | Boveja et al. | Feb 2008 | B2 |
| 7346389 | Newsome | Mar 2008 | B1 |
| 7346398 | Gross et al. | Mar 2008 | B2 |
| 7369897 | Boveja et al. | May 2008 | B2 |
| 7442191 | Hovda et al. | Oct 2008 | B2 |
| 7460911 | Cosendai et al. | Dec 2008 | B2 |
| 7477947 | Pines et al. | Jan 2009 | B2 |
| 7502652 | Gaunt et al. | Mar 2009 | B2 |
| 7547447 | Yiu et al. | Jun 2009 | B2 |
| 7565204 | Matei et al. | Jul 2009 | B2 |
| 7599737 | Yomtov et al. | Oct 2009 | B2 |
| 7636597 | Gross et al. | Dec 2009 | B2 |
| 7650186 | Hastings et al. | Jan 2010 | B2 |
| D613408 | Gausmann et al. | Apr 2010 | S |
| D614303 | Gausmann et al. | Apr 2010 | S |
| D614774 | Gausmann et al. | Apr 2010 | S |
| 7725176 | Schuler et al. | May 2010 | B2 |
| 7725195 | Lima et al. | May 2010 | B2 |
| D617443 | Grenon et al. | Jun 2010 | S |
| 7758190 | Korb et al. | Jul 2010 | B2 |
| 7778703 | Gross et al. | Aug 2010 | B2 |
| 7778711 | Ben-David et al. | Aug 2010 | B2 |
| 7792591 | Rooney et al. | Sep 2010 | B2 |
| 7805200 | Kast et al. | Sep 2010 | B2 |
| 7805202 | Kuzma et al. | Sep 2010 | B2 |
| 7805203 | Ben-David et al. | Sep 2010 | B2 |
| 7809442 | Bolea et al. | Oct 2010 | B2 |
| 7835794 | Greenberg et al. | Nov 2010 | B2 |
| 7846124 | Becker | Dec 2010 | B2 |
| 7860570 | Whitehurst et al. | Dec 2010 | B2 |
| 7873421 | Karell | Jan 2011 | B2 |
| 7879079 | Tu et al. | Feb 2011 | B2 |
| D638128 | Prokop et al. | May 2011 | S |
| 7981095 | Grenon et al. | Jul 2011 | B2 |
| 7993381 | Mac et al. | Aug 2011 | B2 |
| 7998202 | Lesh | Aug 2011 | B2 |
| 8002783 | Vercellotti et al. | Aug 2011 | B2 |
| 8019419 | Panescu et al. | Sep 2011 | B1 |
| 8019441 | Wallace et al. | Sep 2011 | B2 |
| 8080047 | Yu | Dec 2011 | B2 |
| 8145322 | Yao et al. | Mar 2012 | B1 |
| 8155746 | Maltan et al. | Apr 2012 | B2 |
| 8165680 | Greenberg et al. | Apr 2012 | B2 |
| 8204591 | Ben-David et al. | Jun 2012 | B2 |
| 8231218 | Hong et al. | Jul 2012 | B2 |
| 8251983 | Larson et al. | Aug 2012 | B2 |
| 8295529 | Petersen et al. | Oct 2012 | B2 |
| 8318070 | Shiah et al. | Nov 2012 | B2 |
| D681839 | Nathanson | May 2013 | S |
| 8489189 | Tronnes | Jul 2013 | B2 |
| 8494641 | Boling et al. | Jul 2013 | B2 |
| 8626298 | Simon | Jan 2014 | B2 |
| 8676324 | Simon et al. | Mar 2014 | B2 |
| 8728136 | Feldman | May 2014 | B2 |
| 8918181 | Ackermann et al. | Dec 2014 | B2 |
| 8936594 | Wolf et al. | Jan 2015 | B2 |
| 8986301 | Wolf et al. | Mar 2015 | B2 |
| 8996137 | Ackermann et al. | Mar 2015 | B2 |
| 9079042 | Tiedtke et al. | Jul 2015 | B2 |
| 9095723 | Ackermann et al. | Aug 2015 | B2 |
| 9265956 | Ackermann et al. | Feb 2016 | B2 |
| 9440065 | Ackermann et al. | Sep 2016 | B2 |
| 9687652 | Franke et al. | Jun 2017 | B2 |
| 9717627 | Kuzma et al. | Aug 2017 | B2 |
| 9737702 | Ackermann et al. | Aug 2017 | B2 |
| 9737712 | Franke et al. | Aug 2017 | B2 |
| 9764150 | Loudin et al. | Sep 2017 | B2 |
| 9770583 | Gupta et al. | Sep 2017 | B2 |
| 9821159 | Ackermann et al. | Nov 2017 | B2 |
| 9956397 | Loudin et al. | May 2018 | B2 |
| D826420 | Ackermann et al. | Aug 2018 | S |
| 10143846 | Ackermann et al. | Dec 2018 | B2 |
| D837396 | Ackermann et al. | Jan 2019 | S |
| 10207108 | Franke et al. | Feb 2019 | B2 |
| 20010018918 | Burnside et al. | Sep 2001 | A1 |
| 20010020177 | Gruzdowich et al. | Sep 2001 | A1 |
| 20020013594 | Dinger et al. | Jan 2002 | A1 |
| 20020035358 | Wang | Mar 2002 | A1 |
| 20020049290 | Vanderbilt et al. | Apr 2002 | A1 |
| 20020188331 | Fang et al. | Dec 2002 | A1 |
| 20030014089 | Chow et al. | Jan 2003 | A1 |
| 20030045909 | Gross et al. | Mar 2003 | A1 |
| 20030114899 | Woods et al. | Jun 2003 | A1 |
| 20030120323 | Meadows et al. | Jun 2003 | A1 |
| 20030130809 | Cohen et al. | Jul 2003 | A1 |
| 20030139784 | Morimoto et al. | Jul 2003 | A1 |
| 20030176898 | Gross | Sep 2003 | A1 |
| 20030192784 | Zhou et al. | Oct 2003 | A1 |
| 20030233134 | Greenberg et al. | Dec 2003 | A1 |
| 20030233135 | Yee | Dec 2003 | A1 |
| 20040050392 | Tu et al. | Mar 2004 | A1 |
| 20040059466 | Block et al. | Mar 2004 | A1 |
| 20040098036 | Bergersen | May 2004 | A1 |
| 20040098067 | Ohta et al. | May 2004 | A1 |
| 20040127942 | Yomtov et al. | Jul 2004 | A1 |
| 20040138646 | Walla | Jul 2004 | A1 |
| 20040147973 | Hauser et al. | Jul 2004 | A1 |
| 20040151930 | Rouns et al. | Aug 2004 | A1 |
| 20040220644 | Shalev et al. | Nov 2004 | A1 |
| 20050004621 | Boveja et al. | Jan 2005 | A1 |
| 20050004625 | Chow | Jan 2005 | A1 |
| 20050010250 | Schuler et al. | Jan 2005 | A1 |
| 20050010266 | Bogdanowicz | Jan 2005 | A1 |
| 20050101967 | Weber et al. | May 2005 | A1 |
| 20050101994 | Yamazaki et al. | May 2005 | A1 |
| 20050105046 | Tung | May 2005 | A1 |
| 20050137276 | Yahiaoui et al. | Jun 2005 | A1 |
| 20050159790 | Shalev et al. | Jul 2005 | A1 |
| 20050197675 | David et al. | Sep 2005 | A1 |
| 20050251061 | Schuler et al. | Nov 2005 | A1 |
| 20050256570 | Azar | Nov 2005 | A1 |
| 20050267542 | David et al. | Dec 2005 | A1 |
| 20050268472 | Bourilkov et al. | Dec 2005 | A1 |
| 20060004423 | Boveja et al. | Jan 2006 | A1 |
| 20060018872 | Tew et al. | Jan 2006 | A1 |
| 20060074450 | Boveja et al. | Apr 2006 | A1 |
| 20060089673 | Schultheiss et al. | Apr 2006 | A1 |
| 20060095077 | Tronnes et al. | May 2006 | A1 |
| 20060095108 | Chowdhury et al. | May 2006 | A1 |
| 20060100668 | Ben-David et al. | May 2006 | A1 |
| 20060107958 | Sleeper | May 2006 | A1 |
| 20060142822 | Tulgar | Jun 2006 | A1 |
| 20060161225 | Sormann et al. | Jul 2006 | A1 |
| 20060195169 | Gross et al. | Aug 2006 | A1 |
| 20060206155 | Ben-David et al. | Sep 2006 | A1 |
| 20060216317 | Reinhard et al. | Sep 2006 | A1 |
| 20060235430 | Le et al. | Oct 2006 | A1 |
| 20060239482 | Hatoum et al. | Oct 2006 | A1 |
| 20060259098 | Erickson | Nov 2006 | A1 |
| 20060271024 | Gertner et al. | Nov 2006 | A1 |
| 20060271108 | Libbus et al. | Nov 2006 | A1 |
| 20060276738 | Becker | Dec 2006 | A1 |
| 20070038267 | Shodo et al. | Feb 2007 | A1 |
| 20070060815 | Martin et al. | Mar 2007 | A1 |
| 20070060954 | Cameron et al. | Mar 2007 | A1 |
| 20070083245 | Lamensdorf et al. | Apr 2007 | A1 |
| 20070123938 | Haller et al. | May 2007 | A1 |
| 20070135868 | Shi et al. | Jun 2007 | A1 |
| 20070150034 | Rooney et al. | Jun 2007 | A1 |
| 20070219600 | Gertner et al. | Sep 2007 | A1 |
| 20070237797 | Peyman | Oct 2007 | A1 |
| 20070237825 | Levy et al. | Oct 2007 | A1 |
| 20070248930 | Brawn | Oct 2007 | A1 |
| 20070250119 | Tyler et al. | Oct 2007 | A1 |
| 20070250135 | Bartz-Schmidt et al. | Oct 2007 | A1 |
| 20070255333 | Giftakis et al. | Nov 2007 | A1 |
| 20070276314 | Becker | Nov 2007 | A1 |
| 20070276451 | Rigaux | Nov 2007 | A1 |
| 20070295327 | Bottomley | Dec 2007 | A1 |
| 20070299420 | Peyman | Dec 2007 | A1 |
| 20070299462 | Becker | Dec 2007 | A1 |
| 20080009897 | Duran Von Arx | Jan 2008 | A1 |
| 20080021515 | Horsager et al. | Jan 2008 | A1 |
| 20080082057 | Korb et al. | Apr 2008 | A1 |
| 20080082131 | Llanos | Apr 2008 | A1 |
| 20080109054 | Hastings et al. | May 2008 | A1 |
| 20080114424 | Grenon et al. | May 2008 | A1 |
| 20080132933 | Gerber | Jun 2008 | A1 |
| 20080140141 | Ben-David et al. | Jun 2008 | A1 |
| 20080183242 | Tano et al. | Jul 2008 | A1 |
| 20080183243 | Shodo et al. | Jul 2008 | A1 |
| 20080208335 | Blum et al. | Aug 2008 | A1 |
| 20080221642 | Humayun et al. | Sep 2008 | A1 |
| 20080269648 | Bock | Oct 2008 | A1 |
| 20080288036 | Greenberg et al. | Nov 2008 | A1 |
| 20080294066 | Hetling et al. | Nov 2008 | A1 |
| 20090005835 | Greenberg et al. | Jan 2009 | A1 |
| 20090012573 | Karell et al. | Jan 2009 | A1 |
| 20090018582 | Ishikawa et al. | Jan 2009 | A1 |
| 20090024187 | Erickson et al. | Jan 2009 | A1 |
| 20090024189 | Lee et al. | Jan 2009 | A1 |
| 20090036945 | Chancellor et al. | Feb 2009 | A1 |
| 20090043185 | McAdams et al. | Feb 2009 | A1 |
| 20090056709 | Worsoff | Mar 2009 | A1 |
| 20090099600 | Moore et al. | Apr 2009 | A1 |
| 20090099623 | Bentwich et al. | Apr 2009 | A1 |
| 20090099626 | de Juan, Jr. et al. | Apr 2009 | A1 |
| 20090101139 | Karell | Apr 2009 | A1 |
| 20090124965 | Greenberg et al. | May 2009 | A1 |
| 20090138061 | Stephens et al. | May 2009 | A1 |
| 20090156581 | Dillon et al. | Jun 2009 | A1 |
| 20090157142 | Cauller et al. | Jun 2009 | A1 |
| 20090157145 | Cauller | Jun 2009 | A1 |
| 20090157147 | Cauller et al. | Jun 2009 | A1 |
| 20090192571 | Stett et al. | Jul 2009 | A1 |
| 20090192575 | Carbunaru et al. | Jul 2009 | A1 |
| 20090204142 | Becker | Aug 2009 | A1 |
| 20090239235 | DeMaria et al. | Sep 2009 | A1 |
| 20090241840 | Mills | Oct 2009 | A1 |
| 20090264966 | Blum et al. | Oct 2009 | A1 |
| 20090281594 | King et al. | Nov 2009 | A1 |
| 20090281596 | King et al. | Nov 2009 | A1 |
| 20090299418 | Shalev et al. | Dec 2009 | A1 |
| 20090306738 | Weiss et al. | Dec 2009 | A1 |
| 20100030150 | Paques et al. | Feb 2010 | A1 |
| 20100076423 | Muller | Mar 2010 | A1 |
| 20100087896 | McCreery | Apr 2010 | A1 |
| 20100094280 | Muller | Apr 2010 | A1 |
| 20100139002 | Walker et al. | Jun 2010 | A1 |
| 20100152708 | Li et al. | Jun 2010 | A1 |
| 20100161004 | Najafi et al. | Jun 2010 | A1 |
| 20100168513 | Pless et al. | Jul 2010 | A1 |
| 20100179468 | Becker | Jul 2010 | A1 |
| 20100211132 | Nimmagadda et al. | Aug 2010 | A1 |
| 20100241195 | Meadows et al. | Sep 2010 | A1 |
| 20100274164 | Juto | Oct 2010 | A1 |
| 20100274224 | Jain et al. | Oct 2010 | A1 |
| 20100274313 | Boling et al. | Oct 2010 | A1 |
| 20100280509 | Muller et al. | Nov 2010 | A1 |
| 20100288275 | Djupesland et al. | Nov 2010 | A1 |
| 20100318159 | Aghassian et al. | Dec 2010 | A1 |
| 20110021975 | Covello | Jan 2011 | A1 |
| 20110028807 | Abreu | Feb 2011 | A1 |
| 20110028883 | Juan, Jr. et al. | Feb 2011 | A1 |
| 20110077551 | Videbaek | Mar 2011 | A1 |
| 20110077698 | Tsampazis et al. | Mar 2011 | A1 |
| 20110082518 | Filippello | Apr 2011 | A1 |
| 20110093043 | Torgerson et al. | Apr 2011 | A1 |
| 20110151393 | Frey, II | Jun 2011 | A1 |
| 20110152969 | Zehnder et al. | Jun 2011 | A1 |
| 20110184490 | Horsager et al. | Jul 2011 | A1 |
| 20110202121 | Wen | Aug 2011 | A1 |
| 20110218590 | Degiorgio et al. | Sep 2011 | A1 |
| 20110234971 | Yeh | Sep 2011 | A1 |
| 20110270067 | Faraji et al. | Nov 2011 | A1 |
| 20110275734 | Scales et al. | Nov 2011 | A1 |
| 20110276107 | Simon et al. | Nov 2011 | A1 |
| 20110282251 | Baker et al. | Nov 2011 | A1 |
| 20110295336 | Sharma et al. | Dec 2011 | A1 |
| 20110313330 | Loushin et al. | Dec 2011 | A1 |
| 20110313480 | De Vos | Dec 2011 | A1 |
| 20110313481 | De Vos | Dec 2011 | A1 |
| 20120053648 | Neher et al. | Mar 2012 | A1 |
| 20120112903 | Kaib et al. | May 2012 | A1 |
| 20120130398 | Ackermann | May 2012 | A1 |
| 20120133887 | Huang | May 2012 | A1 |
| 20120197338 | Su et al. | Aug 2012 | A1 |
| 20120232615 | Barolat et al. | Sep 2012 | A1 |
| 20120232618 | Feldman | Sep 2012 | A1 |
| 20120234332 | Shantha | Sep 2012 | A1 |
| 20120253249 | Wilson et al. | Oct 2012 | A1 |
| 20120298105 | Osorio et al. | Nov 2012 | A1 |
| 20120315329 | Ahn et al. | Dec 2012 | A1 |
| 20120316557 | Sartor et al. | Dec 2012 | A1 |
| 20120323214 | Shantha | Dec 2012 | A1 |
| 20120323227 | Wolf | Dec 2012 | A1 |
| 20120323232 | Wolf et al. | Dec 2012 | A1 |
| 20120330376 | Flynn et al. | Dec 2012 | A1 |
| 20130006095 | Jenkins et al. | Jan 2013 | A1 |
| 20130006326 | Ackermann et al. | Jan 2013 | A1 |
| 20130053733 | Korb et al. | Feb 2013 | A1 |
| 20130053737 | Scerbo | Feb 2013 | A1 |
| 20130065765 | Selifonov et al. | Mar 2013 | A1 |
| 20130158451 | Juto et al. | Jun 2013 | A1 |
| 20130158626 | DeGiorgio et al. | Jun 2013 | A1 |
| 20130172790 | Badawi | Jul 2013 | A1 |
| 20130178937 | Vassallo et al. | Jul 2013 | A1 |
| 20130253387 | Bonutti et al. | Sep 2013 | A1 |
| 20130261706 | Mirro et al. | Oct 2013 | A1 |
| 20130270491 | Park et al. | Oct 2013 | A1 |
| 20130274824 | Otto et al. | Oct 2013 | A1 |
| 20130274831 | Otto et al. | Oct 2013 | A1 |
| 20130304154 | Goodman et al. | Nov 2013 | A1 |
| 20130310887 | Curtis | Nov 2013 | A1 |
| 20130336557 | Cruzat et al. | Dec 2013 | A1 |
| 20140012182 | Shantha et al. | Jan 2014 | A1 |
| 20140056815 | Peyman | Feb 2014 | A1 |
| 20140081353 | Cook et al. | Mar 2014 | A1 |
| 20140088463 | Wolf et al. | Mar 2014 | A1 |
| 20140163580 | Tischendorf et al. | Jun 2014 | A1 |
| 20140214120 | Simon et al. | Jul 2014 | A1 |
| 20140257205 | Schaller | Sep 2014 | A1 |
| 20140257433 | Ackermann et al. | Sep 2014 | A1 |
| 20140277429 | Kuzma et al. | Sep 2014 | A1 |
| 20140316310 | Ackermann | Oct 2014 | A1 |
| 20140316396 | Wolf et al. | Oct 2014 | A1 |
| 20140316485 | Ackermann et al. | Oct 2014 | A1 |
| 20140362339 | Imafuku | Dec 2014 | A1 |
| 20140371565 | Glasser | Dec 2014 | A1 |
| 20140371812 | Ackermann et al. | Dec 2014 | A1 |
| 20150088156 | Ackermann et al. | Mar 2015 | A1 |
| 20150238754 | Loudin et al. | Aug 2015 | A1 |
| 20150335900 | Ackermann et al. | Nov 2015 | A1 |
| 20150362755 | Lee et al. | Dec 2015 | A1 |
| 20160022992 | Franke et al. | Jan 2016 | A1 |
| 20160058615 | Camras et al. | Mar 2016 | A1 |
| 20160114163 | Franke et al. | Apr 2016 | A1 |
| 20160114172 | Loudin et al. | Apr 2016 | A1 |
| 20160121118 | Franke et al. | May 2016 | A1 |
| 20160158548 | Ackermann et al. | Jun 2016 | A1 |
| 20160270656 | Samec et al. | Sep 2016 | A1 |
| 20160367795 | Ackermann et al. | Dec 2016 | A1 |
| 20160367806 | Kahook | Dec 2016 | A1 |
| 20170049619 | Kahook | Feb 2017 | A1 |
| 20170239459 | Loudin et al. | Aug 2017 | A1 |
| 20170252563 | Franke et al. | Sep 2017 | A1 |
| 20170312521 | Franke et al. | Nov 2017 | A1 |
| 20170340884 | Franke et al. | Nov 2017 | A1 |
| 20170354536 | Kuzma et al. | Dec 2017 | A1 |
| 20170368332 | Ackermann et al. | Dec 2017 | A1 |
| 20170368333 | Loudin et al. | Dec 2017 | A1 |
| 20170368359 | Loudin et al. | Dec 2017 | A1 |
| 20180064940 | Ackermann et al. | Mar 2018 | A1 |
| 20180064941 | Ackermann et al. | Mar 2018 | A1 |
| 20180064942 | Franke et al. | Mar 2018 | A1 |
| 20180153394 | Franke et al. | Jun 2018 | A1 |
| 20180154137 | Ackermann et al. | Jun 2018 | A1 |
| 20180154161 | Ackermann et al. | Jun 2018 | A1 |
| 20180161579 | Franke et al. | Jun 2018 | A1 |
| 20180280688 | Loudin et al. | Oct 2018 | A1 |
| 20190022392 | Franke et al. | Jan 2019 | A1 |
| Number | Date | Country |
|---|---|---|
| 1488331 | Apr 2004 | CN |
| 101087822 | Dec 2007 | CN |
| 101503491 | Aug 2009 | CN |
| 101589085 | Nov 2009 | CN |
| 101939043 | Jan 2011 | CN |
| 102266592 | Dec 2011 | CN |
| 103467652 | Dec 2013 | CN |
| 102006048819 | Apr 2008 | DE |
| 0109935 | May 1984 | EP |
| 1497483 | Jan 2005 | EP |
| 1651307 | May 2006 | EP |
| 1919553 | May 2008 | EP |
| 1958661 | Aug 2008 | EP |
| 2205193 | Jul 2010 | EP |
| 2205314 | Jul 2010 | EP |
| 2102681-0001 | Oct 2012 | EP |
| 2199000-0001 | Mar 2013 | EP |
| 3263175 | Jan 2018 | EP |
| 2 129 690 | Mar 1987 | GB |
| 2 456 002 | Jul 2009 | GB |
| S60500241 | Feb 1985 | JP |
| 2002-519138 | Jul 2002 | JP |
| 2002-325851 | Nov 2002 | JP |
| 2002-539859 | Nov 2002 | JP |
| 2004526510 | Sep 2004 | JP |
| 2005-052461 | Mar 2005 | JP |
| 2005-144178 | Jun 2005 | JP |
| 2005521489 | Jul 2005 | JP |
| 2006-515900 | Jun 2006 | JP |
| 2006-311917 | Nov 2006 | JP |
| 2007-044323 | Feb 2007 | JP |
| 2007-528751 | Oct 2007 | JP |
| 2008-183248 | Aug 2008 | JP |
| 2008-541850 | Nov 2008 | JP |
| 2009-523503 | Jun 2009 | JP |
| 2010-505563 | Feb 2010 | JP |
| 2010-051562 | Mar 2010 | JP |
| 2010506654 | Mar 2010 | JP |
| 2010-537777 | Dec 2010 | JP |
| 2011-030734 | Feb 2011 | JP |
| 2011-524780 | Sep 2011 | JP |
| 2012-100708 | May 2012 | JP |
| 2012-115545 | Jun 2012 | JP |
| WO-0001320 | Jan 2000 | WO |
| WO-0056393 | Sep 2000 | WO |
| WO-0062672 | Oct 2000 | WO |
| WO-02078592 | Oct 2002 | WO |
| WO-03082080 | Oct 2003 | WO |
| WO-2003087433 | Oct 2003 | WO |
| WO-2004026106 | Apr 2004 | WO |
| WO-2004026106 | Apr 2004 | WO |
| WO-2004043217 | May 2004 | WO |
| WO-2004043217 | May 2004 | WO |
| WO-2004091453 | Oct 2004 | WO |
| WO-2004112893 | Dec 2004 | WO |
| WO-2004112893 | Dec 2004 | WO |
| WO-2005007234 | Jan 2005 | WO |
| WO-2005007234 | Jan 2005 | WO |
| WO-2005030025 | Apr 2005 | WO |
| WO-2005030025 | Apr 2005 | WO |
| WO-2005060984 | Jul 2005 | WO |
| WO-2006127366 | Nov 2006 | WO |
| WO-2007079543 | Jul 2007 | WO |
| WO-2008048321 | Apr 2008 | WO |
| WO-2008156501 | Dec 2008 | WO |
| WO-2008156501 | Dec 2008 | WO |
| WO-2009035571 | Mar 2009 | WO |
| WO-2009035571 | Mar 2009 | WO |
| WO-2009048580 | Apr 2009 | WO |
| WO-2009070709 | Jun 2009 | WO |
| WO-2009154457 | Dec 2009 | WO |
| WO-2010003011 | Jan 2010 | WO |
| WO-2010027743 | Mar 2010 | WO |
| WO-2010069317 | Jun 2010 | WO |
| WO-2010099818 | Sep 2010 | WO |
| WO-2010123704 | Oct 2010 | WO |
| WO-2011011373 | Jan 2011 | WO |
| WO-2012068247 | May 2012 | WO |
| WO-2012139063 | Oct 2012 | WO |
| WO-2012139063 | Oct 2012 | WO |
| WO-2012155188 | Nov 2012 | WO |
| WO-2013055940 | Apr 2013 | WO |
| WO-2013055940 | Apr 2013 | WO |
| WO-2013157320 | Oct 2013 | WO |
| WO-2013165697 | Nov 2013 | WO |
| WO-2013166353 | Nov 2013 | WO |
| WO-2014138709 | Sep 2014 | WO |
| WO-2014165124 | Oct 2014 | WO |
| WO-2014172693 | Oct 2014 | WO |
| WO-2014172693 | Oct 2014 | WO |
| WO-2015130707 | Sep 2015 | WO |
| WO-2015130707 | Sep 2015 | WO |
| WO-2016015025 | Jan 2016 | WO |
| WO-2016025323 | Feb 2016 | WO |
| WO-2016065211 | Apr 2016 | WO |
| WO-2016065213 | Apr 2016 | WO |
| WO-2016065215 | Apr 2016 | WO |
| WO-2017192572 | Nov 2017 | WO |
| Entry |
|---|
| Acar, M. et al. (2013). “Ocular surface assessment in patients with obstructive sleep apnea-hypopnea syndrome,” Sleep Breath 17(2):583-588. |
| Amparo (2013). “Topical Interleukin 1 Receptor Antagonist for Treatment of Dry Eye Disease,” JAMA Ophth. 131(6):E1-E9. |
| Bajpai et al. (2012). “Preparation, Characterization and Water Uptake Behavior of Polysaccharide Based Nanoparticles,” Prog. Nanotech. Nanomat. 1(1):9-17. |
| Baraniuk et al. (2007). “Nasonasal Reflexes, the Nasal Cycle, and Sneeze,” Curr. Allergy and Asthma Reports 7:105-111. |
| Baroody FM, Foster KA, Markaryan A, et al. Nasal ocular reflexes and eye symptoms in patients with allergic rhinitis. Ann Allergy Asthma Immunol 2008;100:194-199. |
| Baroody FM, Shenaq D, DeTineo M, et al. Fluticasone furoate nasal spray reduces the nasal-ocular reflex: a mechanism for the efficacy of topical steroids in controlling allergic eye symptoms. J Allergy Clin Immunol 2009;123:1342-1348. |
| Boberg-Ans J. (1955). “Experience in clinical examination of corneal sensitivity: corneal sensitivity and the naso-lacrimal reflex after retrobulbar anaesthesia,” Br. J. Ophthalmol. 39(12):705-726. |
| Calonge (2001). “The Treatment of Dry Eye,” Survey Ophth. 45(2)S227-S239. |
| Cipriano et al. (2014). “Superabsorbent Hydrogels That Are Robust and Highly Stretchable,” Am. Chem Soc. 47(13):4445-4452. |
| Corrected Notice of Allowance dated Feb. 23, 2015, for U.S. Appl. No. 14/256,915, filed Apr. 18, 2014, 2 pages. |
| Dart et al. (2002). “Effects of 25% Propylene Glycol Hydrogel (Solugel) on Second Intention Wound Healing in Horses,” Vet. Surg. 31(4):309-313. |
| Drummond PD. Lacrimation and cutaneous vasodilatation in the face induced by painful stimulation of the nasal ala and upper lip. J Auton Nerv Syst 1995;51:109-16. |
| Elsby et al. (1967). “Lacrimal Secretion in the Cat,” Br. J. Pharm. Chemother. 29(1):1-7. |
| Extended European Search Report (includes Supplementary European Search Report and Search Opinion) received for European Patent Application No. 11842076.9, dated Oct. 10, 2014. |
| Extended European Search Report dated Nov. 18, 2016, for EP Application No. 14 785 631.4, filed on Apr. 18, 2014, 7 pages. |
| Final Office Action received for U.S. Appl. No. 14/256,916, dated Apr. 8, 2015, 16 pages. |
| Final Office Action received for U.S. Appl. No. 14/313,937 dated Apr. 29, 2015, 13 pages. |
| Final Office Action received for U.S. Appl. No. 14/630,471, dated Sep. 26, 2016, 22 pages. |
| Final Office Action received for U.S. Appl. No. 14/256,916, dated Aug. 19, 2016, 19 pages. |
| Final Office Action dated Sep. 23, 2016, for U.S. Appl. No. 14/809,109, filed Jul. 24, 2015, 10 pages. |
| Final Office Action dated Feb. 1, 2017, for U.S. Appl. No. 14/920,852, filed Oct. 22, 2015, 20 pages. |
| Fujisawa et al. (2002). “The Effect of Nasal Mucosal Stimulation on Schirmer Tests in Sjogren's Syndrome and Dry Eye Patients,” Lac. Gland Tear Film Dry Eye Syndrome 3 506:1221-1226. |
| Gupta et al. (1997). “Nasolacrimal Stimulation of Aqueous Tear Production,” Cornea 16(6):645-648. |
| Heigle TJ, Pflugfelder SC. Aqueous tear production in patients with neurotrophic keratitis. Cornea 1996;15:135-8. |
| Holzer P. Capsaicin: cellular targets, mechanisms of action, and selectivity for thin sensory neurons. Pharmacol Rev 1991;43:143-201. |
| Ikemura et al. (2008). “UV-VIS Spectra and Photoinitiation Behaviors of Acylphosphine Oxide and Bisacylphosphine Oxide Derivatives in unfilled, Light-Cured Dental Resins,” Dental Mat. J. 27(6):765-774. |
| International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2011/060989, dated May 30, 2013. |
| International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2012/032629, dated Oct. 17, 2013. |
| International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2014/034733, dated Oct. 29, 2015. |
| International Search Report and Written Opinion received for PCT Application No. PCT/US2015/042130, dated Oct. 28, 2015. |
| International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2014/034733, dated Dec. 5, 2014. |
| International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2015/017379, dated Jul. 24, 2015. |
| International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2015/057023, dated Mar. 4, 2016. |
| International Search Report received for PCT Patent Application No. PCT/US2015/57021, dated Feb. 10, 2016. |
| Krupin T, Cross DA, Becker B. Decreased basal tear production associated with general anesthesia. Arch Ophthalmol 1977;95:107-108. |
| Lora et al. (2009). “Lacrimal Nerve Stimulation by a Neurostimulator for Tear Production,” Invest. Ophth. Vis. Science 50(13):172. |
| Loth S, Bende M. Effect of nasal anaesthesia on lacrimal function after nasal allergen challenge. Clin Exp Allergy 1994;24:375-376. |
| Meng, I.D. et al. (2013). “The role of corneal afferent neurons in regulating tears under normal and dry eye conditions,” Exp. Eye Res. 117:79-87. |
| Mallepally et al. (2013). “Superabsorbent Alginate Aerogels,” J. Supercritical Fluids 79:1-5. |
| Non-Final Office Action received for U.S. Appl. No. 14/256,915, dated Aug. 13, 2014, 11 pages. |
| Non-Final Office Action received for U.S. Appl. No. 14/256,916, dated Sep. 12, 2014, 24 pages. |
| Non-Final Office Action received for U.S. Appl. No. 14/313,937, dated Nov. 19, 2014, 12 pages. |
| Non-Final Office Action dated Jun. 14, 2016, for U.S. Appl. No. 14/630,471, filed Feb. 24, 2015, 24 pages. |
| Non-Final Office Action received for U.S. Appl. No. 14/809,109, dated Apr. 8, 2016, 8 pages. |
| Non-Final Office Action received for U.S. Appl. No. 14/816,846, dated Sep. 11, 2015, 5 pages. |
| Non-Final Office Action Received for U.S. Appl. No. 14/920,860, dated Aug. 17, 2016, 11 pages. |
| Non-Final Office Action received for U.S. Appl. No. 14/256,916, dated Nov. 19, 2015, 20 pages. |
| Non-Final Office Action Received for U.S. Appl. No. 14/313,937, dated Oct. 6, 2015, 7 pages. |
| Non-Final Office Action Received for U.S. Appl. No. 14/920,852, dated Aug. 1, 2016, 20 pages. |
| Non-Final Office Action dated Sep. 30, 2016, for U.S. Appl. No. 15/256,392, filed Sep. 2, 2016, 14 pages. |
| Non-Final Office Action dated Feb. 14, 2017, for U.S. Appl. No. 14/630,471, filed Feb. 24, 2015, 23 pages. |
| Non-Final Office Action dated Apr. 19, 2017, for U.S. Appl. No. 14/256,916, filed Apr. 18, 2014, 19 pages. |
| Notice of Allowance received for U.S. Appl. No. 14/256,915, dated Nov. 26, 2014, 7 pages. |
| Notice of Allowance received for U.S. Appl. No. 14/313,937, dated Feb. 19, 2016, 8 pages. |
| Notice of Allowance received for U.S. Appl. No. 14/313,937, dated May 2, 2016, 7 pages. |
| Notice of Allowability dated Dec. 19, 2016, for U.S. Appl. No. 14/809,109, filed Jul. 24, 2015, 8 pages. |
| Notice of Allowance dated Jan. 19, 2017, for U.S. Appl. No. 14/920,860, filed Oct. 22, 2015, 5 pages. |
| Notice of Allowance dated Mar. 21, 2017, for U.S. Appl. No. 14/809,109, filed Jul. 24, 2015, 8 pages. |
| Notice of Allowance dated Apr. 17, 2017, for U.S. Appl. No. 15/256,392, filed Sep. 2, 2016, 10 pages. |
| Notice of Allowance dated Apr. 20, 2017, for U.S. Appl. No. 14/920,860, filed Oct. 22, 2015, 5 pages. |
| Pasqui et al. (2012). “Polysaccharide-Based Hydrogels: The Key Role of Water in Affecting Mechanical Properties,” Polymers 4(3):1517-1534. |
| Philip G, Baroody FM, Proud D, et al. The human nasal response to capsaicin. J Allergy Clin Immunol 1994;94:1035-1045. |
| Roessler et al. (2009). “Implantation and Explantation of a Wireless Epiretinal Retina Implant Device: Observations During the EPIRET3 Prospective Clinical Trial,” Invest. Ophthal. Visual Science 50(6):3003-3008. |
| Ruskell (2004). “Distribution of Pterygopalatine Ganglion Efferents to the Lacrimal Gland in Man,” Exp. Eye Res. 78(3):329-335. |
| Sall et al. (2000). “Two Multicenter, Randomized Studies of the Efficacy and Safety of Cyclosporine Ophthalmic Emulsion in Moderate to Severe Dry Eye Disease,” Ophth. 107(4):631-639. |
| Shaari et al. (1995). “Rhinorrhea is decreased in dogs after nasal application of botulinum toxin,” Oto. Head Neck Surg. 112(4):566-571. |
| Stjernschantz et al. (1979). “Electrical Stimulation of the Fifth Cranial Nerve in Rabbits: Effects on Ocular Blood Flow, Extravascular Albumin Content and Intraocular Pressure,” Exp. Eye Res. 28(2):229-238. |
| Stjernschantz et al. (1980). “Vasomotor effects of Facial Nerve Stimulation: Noncholinergic Vasodilation in the eye,” Acta Phys. Scand. 109(1):45-50. |
| Tsubota (1991). “The Importance of the Schirmer Test with Nasal Stimulation,” Am. J. Ophth. 111:106-108. |
| Velikay-Parel et al. (2011). “Perceptual Threshold and Neuronal Excitability as Long-Term Safety Evaluation in Retinal Implants,” Invest. Opht. Visual Science E-Abstract 2590, 2 pages. |
| Written Opinion received for PCT Patent Application No. PCT/US2015/57021, dated Feb. 10, 2016. |
| Zilstorff-Pedersen (1965). “Quantitative Measurements of the Nasolacrimal Reflex,” Arch. Oto. 81:457-462. |
| Olsen et al. (1998) “Human Sclera: Thickness and Surface Area.” American Journal of Ophthalmology. Feb. 1998, vol. 125, Issue 2, pp. 237-241. |
| “Vapor Pressure Data for H2O” (2012). Handbook of Chemistry and Physics, 73rd edition, 1 total page. |
| Anonymous (2007). “The epidemiology of dry eye disease: report of the Epidemiology Subcommittee of the International Dry Eye WorkShop (2007),” Ocul. Surf. 5(2):93-107. |
| Eye Health (2014). “Watery eyes in cold weather,” Oregon Eye Specialists, PC, located at http://www.oregoneyes.net/watery-eyes-in-cold-weather/, 3 total pages. |
| Friedman et al. (2016). “A nonrandomized, open-label study to evaluate the effect of nasal stimulation on tear production in subjects with dry eye disease,” Clin. Ophthal. 10:795-804. |
| Friedman, N. J. (2010) “Impact of Dry Eye Disease and Impact on Quality of Life.” Current Opinion in Ophthalmology. 21:310-316. |
| Galor, A. et al. (2014). “Environmental factors affect the risk of dry eye syndrome in a United States veteran population,” Opth. 121:972-973. |
| Harvard Health Publishing (2010). “Dry eyes and what you can try,” Harvard Medical School, 2 total pages. |
| McDonald et al. (2009) “Hydroxypropyl Cellulose Ophthalmic Inserts (Lacrisert) Reduce the Signs and Symptoms of Dry Eye Syndrome and Improve Patient Quality of Life”, Transactions of the American Ophthalmological Society, 107:214-222. |
| Petrov, A. et al. (2016). “SkQ1 Ophthalmic Solution for Dry Eye Treatment: Results of a Phase 2 Safety and Efficacy Clinical Study in the Environment and During Challenge in the Controlled Adverse Environment Model,” Adv. Ther. 33:96-115. |
| Van Setten, G. et al. (2016). “Evidence of seasonality and effects of psychrometry in dry eye disease,” Acta Opth. 94:499-506. |
| Yu, et al. (Apr. 2011) “The Economic Burden of Dry Eye Disease in the United States: a Decision Tree Analysis”, Cornea, 30(4):379-387. |
| Number | Date | Country | |
|---|---|---|---|
| 20170157401 A1 | Jun 2017 | US |
| Number | Date | Country | |
|---|---|---|---|
| 62263498 | Dec 2015 | US | |
| 62321170 | Apr 2016 | US | |
| 62330744 | May 2016 | US | |
| 62376834 | Aug 2016 | US |
